CLINUVEL Files NEURACTHEL Dossier With European Regulators
CUV: $7.22 -1.50% · MC: $375M
CLINUVEL has filed for marketing authorisation of NEURACTHEL Instant in three European Union countries, beginning regulatory review of its second pharmaceutical product. Approval could allow launches in up to three initial markets; the review is intended to take 300 days, excluding possible pauses, and the product is not yet approved anywhere.

Comments